Physician profile
Ryan Lawrence Ragle
NPI 1073781951
$2,726.21
in general payments reported to CMS, 2019-2025
23 companies · $858 in 2025
The $858 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.30 · 2021: $106 · 2022: $31.47 · 2023: $901 · 2024: $810 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.52 |
| Education | $188.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $639.99 | 2023-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $421.37 | 2023-2025 | Tavneos, Evenity, Krystexxa |
| Abbvie INC. | $386.58 | 2022-2025 | |
| Horizon Therapeutics Plc | $179.72 | 2021-2023 | Krystexxa, Tepezza |
| Astrazeneca Pharmaceuticals LP | $140.56 | 2024-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $122.78 | 2023-2025 | Strensiq, Ultomiris |
| Pfizer INC. | $109.94 | 2023-2025 | |
| Ucb, INC. | $109.49 | 2023-2025 | Bimzelx, Cimzia |
| Sobi, INC | $85.27 | 2023-2025 | |
| Lilly USA, LLC | $78.53 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Genzyme Corporation | $72.76 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $69.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $61.43 | 2023-2025 | Benlysta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.02 | 2023-2025 | Cyltezo |
| Kiniksa Pharmaceuticals, LTD. | $35.15 | 2023 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $27.19 | 2023 | Tymlos |
| Kyowa Kirin, INC. | $24.09 | 2025 | |
| Welch Allyn | $19.30 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.19 | 2023 | Lupkynis |
| Genentech USA, INC. | $19.01 | 2024 | Actemra |
| Ani Pharmaceuticals, INC. | $16.49 | 2024 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $15.57 | 2024 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $14.25 | 2025 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Ragle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.